Theravance Biopharma (TBPH) Short Interest Ratio & Short Volume → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free TBPH Stock Alerts $8.44 -0.55 (-6.12%) (As of 04/30/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Theravance Biopharma Short Interest DataCurrent Short Volume6,430,000 sharesPrevious Short Volume7,520,000 sharesChange Vs. Previous Month-14.49%Dollar Volume Sold Short$63.79 millionShort Interest Ratio / Days to Cover17.5Last Record DateApril 15, 2024Outstanding Shares48,560,000 sharesFloat Size43,680,000 sharesShort Percent of Float14.72%Today's Trading Volume368,631 sharesAverage Trading Volume379,726 sharesToday's Volume Vs. Average97% Short Selling Theravance Biopharma ? Sign up to receive the latest short interest report for Theravance Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTBPH Short Interest Over TimeTBPH Days to Cover Over TimeTBPH Percentage of Float Shorted Over Time Ad Porter & CompanyTruth about Trump you’ve never heardEverything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. For the full story, click here. Theravance Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20246,430,000 shares $63.79 million -14.5%14.7%17.5 $9.92 3/31/20247,520,000 shares $67.45 million -10.5%17.2%20.3 $8.97 3/15/20248,400,000 shares $72.58 million -2.4%18.9%23.1 $8.64 2/29/20248,610,000 shares $81.54 million -2.8%19.4%22.7 $9.47 2/15/20248,860,000 shares $76.82 million +6.2%19.3%22.6 $8.67 1/31/20248,340,000 shares $79.06 million -2.3%18.2%20.4 $9.48 Get the Latest News and Ratings for TBPH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/20248,540,000 shares $83.95 million -4.2%18.6%20.8 $9.83 12/31/20238,910,000 shares $100.15 million -4.4%19.4%21.5 $11.24 12/15/20239,320,000 shares $102.43 million -0.1%20.3%23.2 $10.99 11/30/20239,330,000 shares $97.78 million +2.8%20.2%21.8 $10.48 11/15/20239,080,000 shares $92.89 million +1.3%19.7%21.5 $10.23 10/31/20238,960,000 shares $84.58 million -0.4%18.3%20.4 $9.44 10/15/20239,000,000 shares $81.54 million +1.9%18.4%21 $9.06 9/30/20238,830,000 shares $76.20 million -2.7%19.7%20.4 $8.63 9/15/20239,070,000 shares $81.63 million +0.8%20.3%19.8 $9.00 8/31/20239,000,000 shares $85.68 million No Change19.8%19.4 $9.52 8/15/20239,000,000 shares $91.26 million +8.2%19.8%18.6 $10.14 7/31/20238,320,000 shares $82.28 million +1.0%16.7%16.2 $9.89 7/15/20238,240,000 shares $80.67 million +0.2%16.6%15.4 $9.79 6/30/20238,220,000 shares $85.08 million -6.2%16.5%14.3 $10.35 6/15/20238,760,000 shares $91.02 million +0.2%17.6%14.7 $10.39 5/31/20238,740,000 shares $97.71 million +3.2%17.4%16 $11.18 5/15/20238,470,000 shares $95.37 million +9.2%16.9%14.9 $11.26 4/30/20237,760,000 shares $84.04 million +1.8%14.2%14.8 $10.83 4/15/20237,620,000 shares $90.83 million +5.5%14.0%15.3 $11.92 3/31/20237,220,000 shares $78.34 million -4.9%13.1%14.2 $10.85 3/15/20237,590,000 shares $80.15 million -6.4%14.1%15.8 $10.56 2/28/20238,110,000 shares $87.59 million -5.0%15.1%16.9 $10.80 2/15/20238,540,000 shares $88.13 million -3.5%14.7%17.4 $10.32 1/31/20238,850,000 shares $95.67 million +2.1%15.2%13.7 $10.81 1/15/20238,670,000 shares $97.97 million +3.6%14.8%12.5 $11.30 12/30/20228,370,000 shares $93.91 million +1.7%14.3%11.5 $11.22 12/15/20228,230,000 shares $89.05 million +3.4%14.0%10.7 $10.82 11/30/20227,960,000 shares $85.65 million +3.1%13.6%10.2 $10.76 11/15/20227,720,000 shares $87.47 million +3.6%13.3%10.1 $11.33 10/31/20227,450,000 shares $74.28 million -1.2%12.9%11.3 $9.97 10/15/20227,540,000 shares $74.80 million -2.3%13.0%12.4 $9.92 9/30/20227,720,000 shares $78.28 million +2.9%N/A7.6 $10.14 9/15/20227,500,000 shares $75.38 million -3.0%N/A7.9 $10.05 8/31/20227,730,000 shares $69.65 million No Change13.9%8.6 $9.01READ THIS – If You Missed Out On The AI Boom (Ad)Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. TBPH Short Interest - Frequently Asked Questions What is Theravance Biopharma's current short interest? Short interest is the volume of Theravance Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 6,430,000 shares of TBPH short. 14.72% of Theravance Biopharma's shares are currently sold short. Learn More on Theravance Biopharma's current short interest. What is a good short interest ratio for Theravance Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TBPH shares currently have a short interest ratio of 18.0. Learn More on Theravance Biopharma's short interest ratio. What is a good short interest percentage for Theravance Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.72% of Theravance Biopharma's floating shares are currently sold short. Is Theravance Biopharma's short interest increasing or decreasing? Theravance Biopharma saw a decline in short interest in April. As of April 15th, there was short interest totaling 6,430,000 shares, a decline of 14.5% from the previous total of 7,520,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Theravance Biopharma's float size? Theravance Biopharma currently has issued a total of 48,560,000 shares. Some of Theravance Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Theravance Biopharma currently has a public float of 43,680,000 shares. How does Theravance Biopharma's short interest compare to its competitors? 14.72% of Theravance Biopharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Theravance Biopharma: Shattuck Labs, Inc. (4.42%), Acelyrin, Inc. (12.80%), IGM Biosciences, Inc. (25.04%), Travere Therapeutics, Inc. (15.50%), Adlai Nortye Ltd. (0.02%), Fulcrum Therapeutics, Inc. (4.07%), Entrada Therapeutics, Inc. (9.71%), Applied Therapeutics, Inc. (4.15%), KalVista Pharmaceuticals, Inc. (13.79%), Avid Bioservices, Inc. (16.26%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Theravance Biopharma stock? Short selling TBPH is an investing strategy that aims to generate trading profit from Theravance Biopharma as its price is falling. TBPH shares are trading down $0.55 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Theravance Biopharma? A short squeeze for Theravance Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TBPH, which in turn drives the price of the stock up even further. How often is Theravance Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TBPH, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: STTK Short Interest Data SLRN Short Interest Data IGMS Short Interest Data TVTX Short Interest Data ANL Short Interest Data FULC Short Interest Data TRDA Short Interest Data APLT Short Interest Data KALV Short Interest Data CDMO Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TBPH) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersThe Gold Grab of the CenturyColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss RatingsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs Tesla going out of business?DTITrump’s last act as President Porter & CompanyJeff Bezos Just Humiliated Elon MuskInvestorPlaceElon Musk Secret Crypto Plot ExposedCrypto 101 Media